4 unknown, 3 completed, 2 active not recruiting, 2 terminated. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Unknown 4, Completed 3, Active not recruiting 2, Terminated 2, Withdrawn 1 |
Follow Epclusa: new trials by email Literature Review of Epclusa trials Research Report on Epclusa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir - Hepatitis C, Chronic | Phase 4 | Unknown | Partners in Health | 100 | 2019-08-26 | 2019-09-11 |
| HCV Post-Exposure Prophylaxis for Health Care Workers Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-08-13 | 2020-01-21 | |
| Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks - Respiratory Failure, Hepatitis C | Phase 4 | Terminated | Massachusetts General Hospital | 19 | 2019-02-05 | 2023-04-25 |
| Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 400 | 2018-10-22 | 2022-02-04 |
| People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents Epclusa - Diabetes Mellitus, Hepatitis C, Chronic | Phase 4 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 121 | 2018-10-19 | 2026-10-22 |
| Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy Genvoya, Epclusa, Biktarvy - HIV-1-infection, Hepatitis C, Chronic | Phase 4 | Unknown | Saskatchewan Health Authority - Regina Area | 25 | 2018-02-01 | 2019-12-24 |
| Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection Sofosbuvir/Velpatasvir - Hepatitis C, Chronic, Opioid-use Disorder | Phase 4 | Completed | Elizabeth Krans, MD | 32 | 2018-01-30 | 2023-05-06 |
| Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment Epclusa - Hepatitis C, Chronic, Lung Transplant | Phase 4 | Terminated | Duke University | 1 | 2017-09-15 | 2019-09-11 |
| Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial sofosbuvir/velpatasvir - Thalassemia, Hepatitis C | Phase 4 | Completed | Ala'a Sharara | 7 | 2017-05-01 | 2018-10-11 |
| Transplanting Hepatitis C Positive Organs Sofosbuvir/velpatasvir, Monitoring - Hepatitis C, Awaiting Organ Transplant | Phase 4 | Unknown | Brigham and Women's Hospital | 148 | 2017-03-01 | 2022-10-12 |
Hepatitis C (9) · Hepatitis C, Chronic (6) · Fibrosis (2) · Opioid-Related Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Bone Diseases, Metabolic (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Coinfection (1) · Diabetes Mellitus (1) · Liver Diseases (1) · Lung Diseases (1) · Needlestick Injuries (1) · Pregnancy Complications, Infectious (1) · Respiratory Insufficiency (1)
Massachusetts General Hospital (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Ala'a Sharara (1) · Brigham and Women's Hospital (1) · Catherine Anne Chappell (1) · Duke University (1) · Elizabeth Krans, MD (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Partners in Health (1) · Peking University People's Hospital (1) · Saskatchewan Health Authority - Regina Area (1)
United States (8) · Canada (2) · Brazil (1) · Lebanon (1) · Puerto Rico (1) · Rwanda (1) · South Africa (1) · Thailand (1) · Uganda (1)
Alexander Wong, MD (1) · Catherine Chappell, MD, MSc (1) · Elizabeth E Krans, MD, MSc (1) · Fredrick Kateera, MD, PhD (1) · Huiying Rao, Dr. (1) · Lindsey Baden, MD (1) · Marc G Ghany, M.D. (1) · Neil Gupta, MD, MPH (1) · Omar Mohamedaly, MD (1) · Raymond Chung, MD (1) · Raymond T Chung, MD (1) · Sunil Solomon, MBBS, PhD, MPH (1)
PMID 30552056, PMID 30946553, PMID 35026142, PMID 35248212, PMID 35248213, PMID 36694361, PMID 39702964, PMID 40019678, PMID 41255102
UM1AI068636 (1)